AI Article Synopsis
- The systematic review and meta-analysis aims to evaluate the impact of diagnostic hysteroscopy on the prognosis of stage I endometrial cancer, addressing existing uncertainties regarding its oncological safety.
- Two authors will conduct thorough searches of multiple databases to select studies, extract data, and assess study quality, focusing on key outcomes like 5-year recurrence-free survival and overall survival.
- The findings will be disseminated through academic journals and conferences, leveraging previously published data, thus not requiring ethics approval.
Article Abstract
Background: The oncological safety of diagnostic hysteroscopy in patients with stage Ⅰ endometrial cancer remains uncertain and conflicting. The aim of the proposed systematic review and meta-analysis is to summarise the available evidence examining the association between diagnostic hysteroscopy and the prognosis of stage Ⅰ endometrial cancer and to statistically synthesise the results of relevant studies.
Methods And Analysis: Systematic searches of PubMed/MEDLINE, Embase, Cochrane Library and Web of Science will be undertaken using prespecified search strategies. Two authors will independently conduct eligible studies selection process, perform data extraction and appraise the quality of included studies. Original case-control studies, cohort studies and randomised controlled trails published in English will be considered for inclusion. The outcomes of interest will be 5-year recurrence-free survival, disease-specific survival and overall survival. Meta-analyses will be performed to calculate pooled estimates.
Ethics And Dissemination: Our study will be based on published data, and thus there is no requirement for ethics approval. The results will be shared through publication in a peer-reviewed journal and presentations at academic conferences.
Prospero Registration Number: CRD42020193696.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733216 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2020-041981 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical and histopathological evaluation of patients with endometrial cancer in a University Hospital: Seven-year experience.
Malays J Pathol
December 2024
Universiti Sains Malaysia, School of Medical Sciences, Department of Obstetrics & Gynaecology, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia.
Introduction: Endometrial cancer is one of the leading gynaecological malignancies in developed countries and becoming more prevalent in Malaysia. These have significant impact in women and management of this disease. If it occurs on young women, and as a whole becomes a burden on the national economy and world.
View Article and Find Full Text PDFTEFM facilitates uterine corpus endometrial carcinoma progression by activating ROS-NFκB pathway.
J Transl Med
December 2024
Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Background: Mitochondrial transcription elongation factor (TEFM) is a recently discovered factor involved in mitochondrial DNA replication and transcription. Previous studies have reported that abnormal TEFM expression can disrupt the assembly of mitochondrial respiratory chain and thus mitochondrial function. However, the role of TEFM on Uterine corpus endometrial carcinoma (UCEC) progression remains unclear.
View Article and Find Full Text PDFPMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for locally advanced uterine cervical cancer, and durvalumab and olaparib for advanced or recurrent endometrial cancer in Japan.
Int J Clin Oncol
December 2024
Japan Society of Clinical Oncology, Editorial Committee, Tokyo, Japan.
A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer.
Sci Rep
December 2024
Department of Laboratory Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, China.
Endometrial cancer is the most prevalent form of gynecologic malignancy, with a significant surge in incidence among youngsters. Although the advent of the immunotherapy era has profoundly improved patient outcomes, not all patients benefit from immunotherapy; some patients experience hyperprogression while on immunotherapy. Hence, there is a pressing need to further delineate the distinct immune response profiles in patients with endometrial cancer to enhance prognosis prediction and facilitate the prediction of immunotherapeutic responses.
View Article and Find Full Text PDFExploratory Analysis of Radiomics and Pathomics in Uterine Corpus Endometrial Carcinoma.
Sci Rep
December 2024
IRCCS SYNLAB SDN, Via E. Gianturco 113, 80143, Naples, Italy.
Uterine corpus endometrial carcinoma (EC) is one of the most common malignancies in the female reproductive system, characterized by tumor heterogeneity at both radiological and pathological scales. Both radiomics and pathomics have the potential to assess this heterogeneity and support EC diagnosis. This study examines the correlation between radiomics features from Apparent Diffusion Coefficient (ADC) maps and post-contrast T1 (T1C) images with pathomic features from pathology images in 32 patients from the CPTAC-UCEC database.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!